Response to Guo et al, “Response to Huang et al’s ‘Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center (CRDC)’”

Journal of the American Academy of Dermatology · Elsevier

Аннотация

Publication date: November 2026 Source: Journal of the American Academy of Dermatology, Volume 95, Issue 5 Author(s): Lu Yuan, Haochen Huang, Min Hui, Shihan Xu, Dong Xu

Читать у издателя →

Похожие статьи